Drug Device Combination Products Market to Earn US$ 221 Bn by the End 2028

Drug-device Combination Products Market: Introduction

According to the report, the global drug device combination products market was valued at US$ 120.0 Bn in 2020 and is projected to expand at a CAGR of 7.3% from 2021 to 2028. Drug-device combination products are defined as therapeutic products comprising an active pharmaceutical ingredient and a medical device that are physically and/or chemically combined to be produced as a single product.

Read Report Overview - https://www.transparencymarketresearch.com/drug-device-combination.html

Increase in incidence of chronic diseases such as diabetes, cancer, and respiratory problems; rise in casualties due to accidents & trauma, surge in the geriatric population, growth of the home-based healthcare market, and technological advancements such as the development of prefilled syringes boost the growth of the global drug-device combination products market.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1534

Rise in Prevalence of Chronic Diseases to Dominate Global Market

The increase in prevalence of chronic diseases and disorders such as cancer, cardiac conditions, multiple sclerosis, and diabetes is expected to fuel the growth of the global market over the next few years. According to the National Center for Biotechnology Information (NCBI), ischemic heart disease affected around 126 million people (1,655 per 100,000) in 2017, accounting for 1.72% of the global population.

Transdermal Patches to be Highly Lucrative Segment

In terms of product, the global drug device combination products market has been classified into drug eluting stents, infusion pumps, photosensitizers, orthopedic combination products, wound care combination products, inhalers, transdermal patches, and others.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1534

Transdermal patches are the most popular products. This is due to increase in demand for self-administered drugs for diseases that require long-term treatment. Insulin, for instance, must be administered intravenously to diabetic patients on a regular basis. Repeated use of injections to deliver insulin causes pain and increases the risk of infection transmission. Hence, alternative drug delivery modes are expected to gain popularity.

North America to Dominate Global Market

In terms of region, the global drug device combination products market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to be a highly lucrative market for drug-device combination products during the forecast period.

Ask for References - https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=1534

Increase in presence of patented nanomedical products across the region is a major factor driving the market. North America dominated the global drug-device combination products market in terms of revenue in 2020, and the trend is expected to continue during the forecast period.

Asia Pacific is likely to be the most lucrative market for drug-device combination products during the forecast period due to increase in incidence of cardiovascular diseases, diabetes-related disorders, and obesity.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1534

Competition Landscape

The global drug device combination products market is fragmented in terms of number of players. Key players in the global market include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Abbott Laboratories, Medtronic plc, Kaleo, SINOMED, Alcon, Inc., Boston Scientific Corporation, Integer Holdings Corporation, Teleflex Incorporated, Bausch Health Companies, Inc., Haselmeier GmbH, and Flowonix Medical, Inc.

More Trending Reports by Transparency Market Research -

Animal Healthcare Market: https://www.transparencymarketresearch.com/animal-healthcare-industry.html

Erectile Dysfunction Drugs Market: https://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

Regulatory Affairs Outsourcing Market: https://www.transparencymarketresearch.com/global-regulatory-affairs-outsourcing-market.html

Digital Health Market: https://www.transparencymarketresearch.com/digital-health-market.html

Equine Healthcare Market: https://www.transparencymarketresearch.com/equine-healthcare-market.html

Stem Cells Market: https://www.transparencymarketresearch.com/stem-cells-market.html

Medical Imaging Equipment Market: https://www.transparencymarketresearch.com/medical-imaging-equipment-market.html

Home Healthcare Market: https://www.transparencymarketresearch.com/home-healthcare-market.html

Contact

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

This release was published on openPR.